A photo of Punam Malik.

Director, Cincinnati Comprehensive Sickle Cell Center

Program Leader, Hematology and Gene Therapy Program

Marjory J. Johnson Chair, Gene and Cell Therapy

Professor, UC Department of Pediatrics

513-636-1333

513-636-1330

Board Certified

My Biography & Research

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders

Research Divisions

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases, Hematology



Blog Posts

My Locations

My Education

MBBS: University of Delhi, New Delhi, India, 1985.

MD: University of Delhi, New Delhi, India, 1989.

MS: University of Maryland, Baltimore, MD, 1991.

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995.

My Publications

Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Pediatric Blood and Cancer. 2021.

Cardiac pathophysiology in sickle cell disease. Gbotosho, OT; Taylor, M; Malik, P. Journal of Thrombosis and Thrombolysis. 2021.

Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. Cannon, P; Asokan, A; Czechowicz, A; Hammond, P; Kohn, DB; Lieber, A; Malik, P; Marks, P; Porteus, M; Verhoeyen, E; et al. Human Gene Therapy. 2021; 32:31-42.

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience. Karkoska, KA; Todd, KE; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Niss, O; Quinn, CT; Ware, RE; McGann, PT. Blood. 2020; 136:34-34.

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels. Shrestha, A; Chi, M; Wagner, K; Drake, A; Fulzele, K; Guichard, S; Malik, P. Blood. 2020; 136:21-22.

Bone Marrow (BM) Delivery of Genetically-Modified (gm) Adult CD34+ Hematopoietic Stem and Progenitor Cells (HSPC) Improves Homing and Engraftment of Short-Term Progenitors over Long-Term Repopulating Hematopoietic Stem Cells. Felker, S; Shrestha, A; Malik, P. Blood. 2020; 136:22-23.

Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study. Niss, O; Lane, A; Asnani, MR; Yee, ME; Raj, A; Creary, S; Fitzhugh, C; Bodas, P; Saraf, SL; Sarnaik, S; et al. Blood Advances. 2020; 4:1501-1511.

Effective hematopoietic stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis. Hetzel, M; Lopez-Rodriguez, E; Mucci, A; Ha Nguyen, AH; Suzuki, T; Shima, K; Buchegger, T; Dettmer, S; Rodt, T; Bankstahl, JP; et al. Haematologica. 2020; 105:1147-1157.

End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings. Farrell, AT; Panepinto, J; Desai, AA; Kassim, AA; Lebensburger, J; Walters, MC; Bauer, DE; Blaylark, RM; DiMichele, DM; Gladwin, MT; et al. Blood Advances. 2019; 3:4002-4020.